Another clinical trial of CAR-T cells in the treatment of B-ALL (NCT02315612) showed that 8 of 12 patients (67%) who had CR after CD22 CAR-T-cell therapy relapsed, and 7 of these patients had downregulated CD22 expression. Here, CD22 is linked to acute lymphoblastic leukemia.